Home / Companies and Markets / How Western Union, Pfizer, and Gilead Sciences Performed

How Western Union, Pfizer, and Gilead Sciences Performed

We continue with the review of quarterly financial reports. Let’s take a look at how the following companies performed: The Western Union Company (NYSE:WU), Pfizer Inc. (NYSE:PFE), and Gilead Sciences Inc. (NASD:GILD). These are global brands and well-known companies. How did stock prices react to the announcement of quarterly results? Let’s see below.

The Western Union Company (NYSE:WU)

The Western Union Company is a leading company providing payment services worldwide. The company has a market capitalization of $9.63 billion and its stock is listed in the S&P 500 index. The current stock price is $19.74, and over the last 12 months, it has ranged from $16.02 to $21.80. The announcement of quarterly reports resulted in a price drop of 1.64% compared to the previous day. The quarterly business results are as follows. Earnings per share for the third quarter of this year amount to $0.44, which is the same amount that analysts expected, and is $0.01 less than the earnings per share in the same period last year, which was $0.45. Revenues for the third quarter of this year amount to $1.4 billion, which is $0.01 billion more than analysts expected, but the same as the revenues in the same period last year, which also amounted to $1.4 billion. The stock has gained 10.22% since the beginning of the year, and over the last 12 months, it has gained 2.55%. The dividend yield for the stock is 3.24%, which is higher than the yield of the S&P 500 index, which is 2.06%.

Optimtrader

Pfizer Inc. (NYSE:PFE)

Pharmaceutical giant Pfizer Inc. is a company engaged in the research, production, and distribution of drugs and various treatments. The company has been operating for 167 years. The current market capitalization is $188.46 billion, and the stocks are included in the DJIA and S&P 500 indices. The current stock price is $31.07, and over the last 12 months, it has ranged from $28.25 to $37.39. The announcement of quarterly financial reports resulted in a stock price drop of 2.02% compared to the previous day, and let’s see what the results are below. Earnings per share in the third quarter of this year amount to $0.61, which is $0.01 less than analysts’ expectations, who forecasted a level of $0.62. Earnings per share in the third quarter of last year were $0.60, which is $0.01 less than this year. Revenues have been growing for the third consecutive quarter, and in the third quarter of this year, they amount to $13.05 billion, which is the same amount that analysts expected, and is 7.85% higher than the revenues in the same period last year, which were at the level of $12.1 billion. The company pays a stable dividend with a dividend yield of 3.86%. The stock price has lost 3.75% since the beginning of the year, while over the last 12 months, it has decreased by 8.13%.

Gilead Sciences Inc. (NASD:GILD)

Gilead Sciences Inc. is a leading company in the biopharmaceutical industry focused on researching drugs for currently incurable diseases. The market capitalization of the corporation is a substantial $97.75 billion, and the stock is included in the S&P 500 index. The current stock price is $74.07, and over the last 12 months, it has ranged from $72.21 to $109.95. What does the announcement of quarterly financial reports bring? Let’s see below. Earnings per share in the third quarter of this year amount to $2.75, which is $0.11 less than analysts’ expectations, who predicted a level of $2.86. In the same period last year, earnings per share were $3.22, which is 17.09% higher than earnings per share in the third quarter of this year. Revenues have been declining for the third consecutive quarter, and in the third quarter of this year, they amount to $7.4 billion, which is slightly below analysts’ expectations, who forecasted a level of $7.45 billion. In the same period last year, revenues were $8.3 billion, which is 12.16% higher than in the third quarter of the current year. The stock has lost 26.80% since the beginning of the year.

For OptimTrader Ivan Stojanović, Head of Croatian Market at CM-Equity AG (OptimTrader)

For any inquiries, please write to [email protected]